Immunoglobulin/blood product
|
Route
|
Dose (IU or mL)
|
Dose (estimated mg IgG/kg)
|
Interval (months)
|
Blood transfusion: washed red blood cells
|
IV
|
10 mL/kg
|
Negligible
|
0
|
Blood transfusion: red blood cells, adenine-saline added
|
IV
|
10 mL/kg
|
10
|
3
|
Blood transfusion: packed red blood cells
|
IV
|
10 mL/kg
|
20–60
|
5
|
Blood transfusion: whole blood
|
IV
|
10 mL/kg
|
80–100
|
6
|
Cytomegalovirus immunoglobulin
|
IV
|
3 mL/kg
|
150
|
6
|
Hepatitis B immunoglobulin as hepatitis B prophylaxis
|
IM
|
100 IU or 400 IU
|
10
|
3
|
NHIG (intravenous) for treatment of idiopathic thrombocytopenic purpura
|
IV
|
na
|
400
|
8
|
NHIG (intravenous) for treatment of idiopathic thrombocytopenic purpura
|
IV
|
na
|
1000
|
10
|
NHIG (intravenous) for treatment of idiopathic thrombocytopenic purpura or Kawasaki disease
|
IV
|
na
|
1600–2000
|
11
|
NHIG as hepatitis A prophylaxis
|
IM
|
0.5 mL (<25 kg), 1.0 mL (25–50 kg), 2.0 mL (>50 kg)
|
na
|
3
|
NHIG as measles prophylaxis: standard
|
IM
|
0.2 mL/kg (maximum dose 15 mL)
|
na
|
5
|
NHIG as measles prophylaxis: immunocompromised
|
IM
|
0.5 mL/kg (maximum dose 15 mL)
|
na
|
6
|
Plasma or platelet products
|
IV
|
10 mL/kg
|
160
|
7
|
Human rabies immunoglobulin as rabies prophylaxis
|
IM
|
20 IU/kg
|
22
|
4
|
Replacement (or therapy) of immune deficiencies as NHIG (intravenous), various doses
|
IV
|
na
|
300–400
|
9
|
Rh (D) immunoglobulin (anti-D)
|
IM
|
na
|
na
|
0
|
Tetanus immunoglobulin (intramuscular use) as tetanus prophylaxis
|
IM
|
250 IU (given within 24 hours of injury)
|
10
|
3
|
Tetanus immunoglobulin (intramuscular use) as tetanus prophylaxis
|
IM
|
500 IU (>24 hours after injury)
|
20
|
3
|
Zoster immunoglobulin as varicella prophylaxis
|
IM
|
200 IU (0–10 kg), 400 IU (11–30 kg), 600 IU (>30 kg)
|
na
|
5
|